Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD.
Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD.
复制标题
血液透析或 CAPD 患者血清中晚期糖基化终产物的免疫学定量。
作者：
Panayiotis Papanastasiou;L. Grass;H. Rodela;Athena Patrikarea;D. Oreopoulos;E. Diamandis
我们已经开发了一种免疫学方法来测量血清中的晚期糖基化终产物（AGEs）。使用这种方法，我们测量了AGEs在健康志愿者，糖尿病患者，肾功能衰竭，未经治疗的患者，肾功能衰竭，血液透析（HD）或持续非卧床腹膜透析（CAPD）治疗。我们发现AGEs在无肾功能衰竭的糖尿病患者中中度升高，在CAPD和HD患者中高度升高，无论其血糖状态如何。AGE水平与肌酐水平显著相关，但与血糖水平、患者年龄或性别无关。血液透析后AGE水平显着降低。初步实验表明，循环AGEs的分子量约为1.5至2.0 kDa。需要更多的研究来确定血清中AGE的测量是否是糖尿病或肾衰竭并发症的预后指标。
We have developed an immunological procedure for measuring advanced glycosylation end-products (AGEs) in serum. Using this method, we measured AGEs in healthy volunteers, patients with diabetes, renal failure without treatment and in patients with renal failure, treated with hemodialysis (HD) or continuous ambulatory peritoneal dialysis (CAPD). We found that AGEs were moderately elevated in diabetics without renal failure and highly elevated in CAPD and HD patients irrespective of their glycemic status. AGE levels correlated significantly with creatinine levels but not with levels of glucose or patient age or sex. AGE levels were reduced significantly post-hemodialysis. Preliminary experiments have shown that circulating AGEs have a molecular weight of approximately 1.5 to 2.0 kDa. More studies are needed to establish if AGE measurements in serum are prognostic indicators of the complications of either diabetes or renal failure.
DOI：
10.1073/pnas.78.8.5190
发表时间：
1981-08
影响因子：
11.1
作者：
H. Vlassara;M. Brownlee;A. Cerami
通讯作者：
H. Vlassara;M. Brownlee;A. Cerami
影响因子：
158.5
作者：
MAKITA, Z;RADOFF, S;VLASSARA, H
通讯作者：
VLASSARA, H